Genetic Technologies Limited, a leading molecular diagnostics company, is expanding its reach to provide predictive genetic testing and risk assessment tools to physicians across multiple continents. The company operates through two main segments - EasyDNA and GeneType/Corporate - and offers an array of services aimed at helping clinicians manage their patients' health. Genetic Technologies Limited's flagship product is BREVAGenplus, a fully validated risk assessment test for non-hereditary breast cancer, which is marketed to healthcare professionals working in breast health care and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. Aside from this, the company provides cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names, along with genetic testing services for medical, animal, forensic, and plant testing. Furthermore, it is continuously developing risk assessment tests for various diseases, including colorectal cancer, ovarian cancer, prostate cancer, and type 2 diabetes. With research and collaboration agreements with renowned institutions such as the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom, Genetic Technologies Limited is committed to advancing the field of molecular diagnostics. The company, founded in 1987, is headquartered in Fitzroy, Australia.
Genetic Technologies Ltd's ticker is GENE
The company's shares trade on the NASDAQ stock exchange
They are based in Fitzroy, Australia
There are 51-200 employees working at Genetic Technologies Ltd
It is https://www.gtglabs.com/
Genetic Technologies Ltd is in the Healthcare sector
Genetic Technologies Ltd is in the Biotechnology industry
The following five companies are Genetic Technologies Ltd's industry peers: